BridgeBio Oncology Therapeutics, Inc.
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$134.0M
- Total assets
- $448.4M
- Market cap
- $625.6M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $145.8M
- Operating income
- -$145.8M
- Income tax
- $0
- Net income
- -$134.0M
- EPS (basic)
- $-4.30
- EPS (diluted)
- $-4.30
Balance sheet
- Total assets
- $448.4M
- Current assets
- $432.4M
- Total liabilities
- $37.3M
- Current liabilities
- $35.0M
- Shareholders’ equity
- $411.1M
Cash flow
- Operating cash flow
- -$113.9M
- Investing cash flow
- $73.3M
- Financing cash flow
- $383.4M
- Net cash flow
- $342.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $625.6M
- EPS (diluted)
- $-4.3
- Shares outstanding
- 80.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 12, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $134.0M.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BridgeBio Oncology Therapeutics, Inc..
Write a review
News about BridgeBio Oncology Therapeutics, Inc.
News & sentiment via Polygon.io
